Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Substance in cancer medicine could prevent heart attacks

23.11.2011
A substance in medicines for cancer and epilepsy could also prevent heart attacks, according to researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden,, who have been using it to stimulate the body’s own defence system against blood clots.

Heart attacks are normally caused by the formation of a blood clot in one of the blood vessels that supply the heart with oxygen and nutrients. The clot reduces the supply of oxygen, which can very quickly result in irreparable damage to the heart.

The body´s own protection

The body has a natural defence system to prevent blood clots – the fibrinolytic system – which ““sprays““ a special enzyme over the clots to break them down before they manage to obstruct the vessel. However, in order to function properly, this system needs sufficient quantities of the enzyme to be stored in the vessel wall. Unfortunately these stores are often depleted because of hereditary and lifestyle factors, such as high blood pressure, smoking and overweight, which probably increases the risk of a heart attack.

New ways of preventing heart attack

Researchers at the University of Gothenburg’s Sahlgrenska Academy have been looking at a way to stimulate the clot-dissolving system. The results are promising and open the door to new ways of preventing heart attacks.

“We’re trying to find a medicine that boosts the stores of the enzyme as this probably would help the body to prevent heart attacks,” says Pia Larsson at the Sahlgrenska Academy, who is basing her thesis on the study.

Stimulates enzyme production

Previously tested substances have proved unsuitable, mainly because of their unwanted side-effects. In the present study the Sahlgrenska researchers used HDAC inhibitors, substances new to this particular context, and managed to stimulate production of the relevant enzyme.

“We found that treatment with HDAC inhibitors dramatically increased production of the clot-dissolving enzyme, and that this occurred at far lower concentrations than expected,” says Larsson.

Side-effects well known

The advantage of HDAC inhibitors is that they are already used in medication for illnesses such as epilepsy and cancer, which means that their pharmacological properties and side-effects are known.

Larsson says that more research is needed before a drug to prevent heart attacks can be launched.

“Our trials have been carried out on cultured cells from the vessel wall and we can’t guarantee that the cells, when present in the body, will behave in exactly the same way. The results must therefore be tested on people before we can draw any firm conclusions.”

Furhter investigation

The Sahlgrenska researchers are therefore preparing the first in a series of studies on human subjects to further investigate the effect of HDAC inhibitors on the clot-dissolving enzyme.

The thesis, “Regulation of Vascular Endothelial t-PA Expression in Inflammation – Potential Target for Pharmacological Modulation” was defended on 18 November.

For more information, please contact: Pia Larsson
Telephone: +46 (0)736 240 394
E-mail: pia.larsson@gu.se

Helena Aaberg | idw
Further information:
http://www.gu.se

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>